- Conditions
- Glioblastoma
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 94
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Malignant Glioma
- Interventions
- lerapolturev, Lomustine
- Biological · Drug
- Lead sponsor
- Istari Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 2 more
- Conditions
- Glioblastoma, Glioblastoma (GBM), Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Gliosarcoma, Adult, Gliosarcoma of Brain
- Interventions
- C134
- Drug
- Lead sponsor
- James Markert, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Gliomas, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Glioma, Glioblastoma Multiforme, Malignant Meningioma
- Interventions
- alloreactive CTL
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioma
- Interventions
- Rhenium Liposome Treatment
- Drug
- Lead sponsor
- Plus Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 3
- States / cities
- Manhasset, New York • Dallas, Texas • San Antonio, Texas
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
- Conditions
- Glioblastoma
- Interventions
- Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
- Biological · Drug
- Lead sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma Multiform (Grade IV Astrocytoma)
- Interventions
- PolyMVA
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Glioblastoma, Malignant Glioma
- Interventions
- Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma, Adult Brain Tumor, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Adult Anaplastic Oligoastrocytoma, Recurrent High Grade Glioma
- Interventions
- flucytosine, polymerase chain reaction, immunohistochemistry staining method, gene therapy, pharmacological study, 3-Tesla magnetic resonance imaging, laboratory biomarker analysis, therapeutic conventional surgery, E. coli CD-expressing genetically modified neural stem cells
- Drug · Other · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Astrocytoma, Glioblastoma, Progressive Disease
- Interventions
- FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology
- Biological · Procedure · Diagnostic Test
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
- Interventions
- INC280, Buparlisib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
- Conditions
- Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
- Interventions
- Nivolumab-Placebo, Nivolumab, Ipilimumab-Placebo, Ipilimumab, Surgery
- Drug · Procedure
- Lead sponsor
- Patrick Wen, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Stanford, California • Boston, Massachusetts + 1 more
- Conditions
- Glioblastoma
- Interventions
- Cilengitide, Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
- Interventions
- Intensity-Modulated Radiation Therapy, Quality-of-Life
- Radiation · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioblastoma WHO Grade IV
- Interventions
- Quisinostat
- Drug
- Lead sponsor
- Nader Sanai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- GBM, Glioblastoma Multiforme
- Interventions
- DCVax-L
- Biological
- Lead sponsor
- Northwest Biotherapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 23 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- ERC1671, GM-CSF, Cyclophosphamide, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar
- Drug
- Lead sponsor
- Epitopoietic Research Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 3
- States / cities
- Orange, California • Boston, Massachusetts
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Interventions
- Ribociclib, Everolimus, Temozolomide (TMZ)
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 12 Months to 39 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
- Interventions
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Orlando, Florida • Durham, North Carolina
- Conditions
- Glioblastoma, Astrocytoma, Grade IV
- Interventions
- XL765 (SAR245409), XL147 (SAR245408)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more
- Conditions
- Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents
- Interventions
- CYNK001-IV, CYNK001-IT
- Biological
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
- Interventions
- Olutasidenib + TMZ
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 39 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more
- Conditions
- Malignant Glioma, Astrocytoma, Glioblastoma
- Interventions
- nivolumab, DC
- Drug · Biological
- Lead sponsor
- Gary Archer Ph.D.
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina